(Q38112386)

29 August 2017

title

Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice (English)

1 reference

29 August 2017

0 references

1 reference

1

1 reference

29 August 2017

2

1 reference

29 August 2017

5

Paolo Graziano

1 reference

29 August 2017

Giuseppe Pelosi

3

1 reference

29 August 2017

Mattia Barbareschi

series ordinal

4

1 reference

29 August 2017

Alberto Cavazza

series ordinal

6

1 reference

29 August 2017

Mauro Papotti

series ordinal

7

1 reference

29 August 2017

publication date

5 June 2013

1 reference

International Journal of Surgical Pathology

29 August 2017

published in

1 reference

29 August 2017

volume

21

1 reference

29 August 2017

issue

4

1 reference

29 August 2017

page(s)

326-336

1 reference

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Crizotinib and testing for ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Histology matters: individualizing treatment in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Should we continue to use the term non-small-cell lung cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Swedish lung cancer radiation study group: predictive value of histology for radiotherapy response in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Impact of histopathological diagnosis with ancillary immunohistochemical studies on lung cancer subtypes incidence and survival: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

The classification of lung carcinoma: time to change the morphology-based approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

A reevaluation of the clinical significance of histological subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Unique microRNA molecular profiles in lung cancer diagnosis and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

A systematic review of the interobserver variability for histology in the differentiation between squamous and nonsquamous non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Immunhistochemistry by Means of Widely Agreed-Upon Markers (Cytokeratins 5/6 and 7, p63, Thyroid Transcription Factor-1, and Vimentin) on Small Biopsies of Non-small Cell Lung Cancer Effectively Parallels the Corresponding Profiling and Eventual Diag

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

p63 immunostaining in destained bronchoscopic cytological specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

ΔNp63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer: A Novel Two-Hit, Sparing-Material Approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Simultaneous multi-antibody staining in non-small cell lung cancer strengthens diagnostic accuracy especially in small tissue samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Expression of squamous cell carcinoma markers and adenocarcinoma markers in primary pulmonary neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Thyroid transcription factor-1 expression in breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Thyroid transcription factor-1 is not expressed in squamous cell carcinomas of the lung: an immunohistochemical study with review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1066896913489346

21 January 2018

Identifiers

DOI

10.1177/1066896913489346

1 reference

29 August 2017

1 reference